Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiangju Rupining is a traditional Chinese medicine (TCM) oral preparation formulated as a capsule. It is used primarily for the treatment of hyperplasia of mammary glands, particularly in patients diagnosed with "liver depression and phlegm stagnation syndrome" according to TCM principles. Clinical studies are evaluating its efficacy and safety in reducing breast pain and improving quality of life compared to placebo. The mechanism of action is based on TCM theory rather than a defined molecular target; it aims to relieve symptoms by addressing liver qi stagnation and phlegm accumulation[1][2][3]. The product is developed by Wuhan Medicine Valley Technology Development Co., Ltd.[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiangju rupining.